Trump's Greenland Tariff Threat Could Hike Ozempic, Wegovy Prices
President-elect Trump's threat to impose high tariffs on Denmark unless it sells Greenland to the US could significantly increase the price of the popular diabetes and weight-loss drugs Ozempic and Wegovy, which are manufactured by Novo Nordisk. The US imported $5.7 billion in pharmaceuticals from D...
Trump's Greenland Tariff Threat Could Hike Ozempic, Wegovy Prices
President-elect Trump's threat to impose high tariffs on Denmark unless it sells Greenland to the US could significantly increase the price of the popular diabetes and weight-loss drugs Ozempic and Wegovy, which are manufactured by Novo Nordisk. The US imported $5.7 billion in pharmaceuticals from D...
Progress
40% Bias Score
Ozempic Linked to Doubled Risk of Rare Eye Disease
Two studies from the University of Southern Denmark reveal a doubled risk of developing a rare, irreversible eye disease among Ozempic users compared to non-users; health authorities are monitoring the situation closely.
Ozempic Linked to Doubled Risk of Rare Eye Disease
Two studies from the University of Southern Denmark reveal a doubled risk of developing a rare, irreversible eye disease among Ozempic users compared to non-users; health authorities are monitoring the situation closely.
Progress
44% Bias Score
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
Progress
52% Bias Score
Kathy Bates Showcases Dramatic Weight Loss at Hollywood Gala
Kathy Bates, 76, displayed her 100-pound weight loss at the Hollywood Reporter's Women in Entertainment Gala in Beverly Hills on Wednesday, openly discussing her health journey and use of Ozempic, while also reflecting on ageism in Hollywood.
Kathy Bates Showcases Dramatic Weight Loss at Hollywood Gala
Kathy Bates, 76, displayed her 100-pound weight loss at the Hollywood Reporter's Women in Entertainment Gala in Beverly Hills on Wednesday, openly discussing her health journey and use of Ozempic, while also reflecting on ageism in Hollywood.
Progress
56% Bias Score
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Progress
24% Bias Score
Kelly Osbourne's Birthday Celebrations and Weight Loss Comments
Kelly Osbourne celebrated her son's birthday with a star-studded party and recently celebrated her own birthday with a glamorous event. She also addressed rumors surrounding her weight loss.
Kelly Osbourne's Birthday Celebrations and Weight Loss Comments
Kelly Osbourne celebrated her son's birthday with a star-studded party and recently celebrated her own birthday with a glamorous event. She also addressed rumors surrounding her weight loss.
Progress
40% Bias Score
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Progress
52% Bias Score
Ozempic and Increased Risk of Blindness: New Studies Reveal Elevated NAION Risk
New studies in Denmark and Norway reveal that Ozempic, a popular diabetes medication used for weight loss, more than doubles the risk of NAION (non-arteritic anterior ischemic optic neuropathy), a severe eye disease potentially causing blindness, compared to alternative treatments; these findings co...
Ozempic and Increased Risk of Blindness: New Studies Reveal Elevated NAION Risk
New studies in Denmark and Norway reveal that Ozempic, a popular diabetes medication used for weight loss, more than doubles the risk of NAION (non-arteritic anterior ischemic optic neuropathy), a severe eye disease potentially causing blindness, compared to alternative treatments; these findings co...
Progress
52% Bias Score
High-Protein Bar David Capitalizes on Ozempic Trend
Peter Rahal, after selling RxBar for $600 million, launched a new high-protein bar called David, which sold over 1 million units in its first six weeks, driven by increased demand from users of weight-loss drugs like Ozempic.
High-Protein Bar David Capitalizes on Ozempic Trend
Peter Rahal, after selling RxBar for $600 million, launched a new high-protein bar called David, which sold over 1 million units in its first six weeks, driven by increased demand from users of weight-loss drugs like Ozempic.
Progress
44% Bias Score
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
US to Subsidize Obesity Medications for Millions
The US will spend $35 billion over 10 years to subsidize Wegovy and Mounjaro for millions of Americans with a BMI of 30 or higher, aiming to reduce obesity-related healthcare costs.
Progress
40% Bias Score
Kennedy's Misinformation on Ozempic Sparks Medical Outrage
Doctors criticize Robert F. Kennedy Jr.'s inaccurate claims about Ozempic and other obesity and diabetes medications, raising concerns about his nomination as Health and Human Services Secretary.
Kennedy's Misinformation on Ozempic Sparks Medical Outrage
Doctors criticize Robert F. Kennedy Jr.'s inaccurate claims about Ozempic and other obesity and diabetes medications, raising concerns about his nomination as Health and Human Services Secretary.
Progress
40% Bias Score